Published in J Natl Cancer Inst on April 21, 2004
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med (2008) 3.02
Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68
Evaluating human papillomavirus vaccination programs. Emerg Infect Dis (2004) 2.47
The known unknowns of HPV natural history. J Clin Invest (2011) 2.39
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med (2006) 2.10
Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol (2010) 1.94
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ (2007) 1.72
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer (2006) 1.57
Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG (2012) 1.57
Human papillomavirus and HPV vaccines: a review. Bull World Health Organ (2007) 1.55
Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer (2008) 1.48
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol (2009) 1.45
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis (2008) 1.35
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med (2009) 1.29
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets. Proc Natl Acad Sci U S A (2008) 1.22
Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs. South Asian J Cancer (2013) 1.09
Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol (2009) 1.05
HPV and cervical cancer prevention counseling with younger adolescents: implications for primary care. Ann Fam Med (2007) 0.95
Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS One (2011) 0.94
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health (2009) 0.94
Towards a more comprehensive understanding of cancer burden in North Carolina: priorities for intervention. N C Med J (2008) 0.94
Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia without colposcopic tissue information; a step toward automation for low resource settings. J Biomed Opt (2012) 0.93
Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS One (2013) 0.92
Potential benefits of second-generation human papillomavirus vaccines. PLoS One (2012) 0.91
Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirus. J Virol Methods (2009) 0.90
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health (2010) 0.90
Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health (2010) 0.89
A Virus-based Vaccine May Prevent Cervical Cancer. Curr Infect Dis Rep (2005) 0.88
Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women. Sex Transm Dis (2009) 0.87
Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role. Cancer (2008) 0.87
Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest. PLoS One (2013) 0.87
Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine (2013) 0.87
c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia. Oncotarget (2015) 0.87
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health (2011) 0.85
Optical technologies and molecular imaging for cervical neoplasia: a program project update. Gend Med (2011) 0.85
Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods (2012) 0.85
Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study. BMJ Open (2012) 0.84
Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol (2006) 0.83
Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res (2010) 0.83
Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran. Iran J Pharm Res (2014) 0.83
Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PLoS One (2013) 0.82
Too much of a good thing? When to stop catch-up vaccination. Med Decis Making (2013) 0.82
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag (2008) 0.81
Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol (2011) 0.81
Human papillomavirus vaccine for children and adolescents. Paediatr Child Health (2007) 0.79
HPV vaccine acceptance, utilization and expected impacts in the U.S.: Where are we now? Hum Vaccin (2010) 0.79
CIN III lesions and regression: retrospective analysis of 635 cases. BMC Infect Dis (2015) 0.78
Pediatricians are more supportive of the human papillomavirus vaccine than the general public. South Med J (2008) 0.78
The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model. Hum Vaccin Immunother (2016) 0.78
Acceptability of cancer chemoprevention trials: impact of the design. Int J Med Sci (2008) 0.78
Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening. Br J Cancer (2015) 0.78
Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78
Correlates of human papillomavirus vaccine coverage: a state-level analysis. Sex Transm Dis (2015) 0.78
Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC Cancer (2016) 0.78
Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis. PLoS One (2016) 0.77
A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema. Cancer (2010) 0.77
Mathematical model of HPV provides insight into impacts of risk factors and vaccine. PLoS Med (2006) 0.77
Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health (2012) 0.76
Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One (2013) 0.76
Modeling optimal cervical cancer prevention strategies in Nigeria. BMC Cancer (2014) 0.76
Human papilloma virus (HPV) vaccination in childhood: challenges and perspectives. Hippokratia (2011) 0.76
Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Factors influencing uptake of HPV vaccination among girls in Germany. BMC Public Health (2016) 0.75
Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health (2017) 0.75
Examining Provincial HPV Vaccination Schemes in Canada: Should We Standardise the Grade of Vaccination or the Number of Doses? Int Sch Res Notices (2015) 0.75
The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control (2016) 0.75
Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? BMC Infect Dis (2015) 0.75
Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. BMC Infect Dis (2015) 0.75
Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend. BMC Public Health (2017) 0.75
Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China. BMC Cancer (2016) 0.75
Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran. Iran J Pharm Res (2015) 0.75
Human papillomavirus-related gynecologic neoplasms: screening and prevention. Rev Obstet Gynecol (2008) 0.75
Human Papillomavirus Vaccination Uptake in Canada: A Systematic Review and Meta-analysis. Int J Prev Med (2017) 0.75
Using simulation-optimization to construct screening strategies for cervical cancer. Health Care Manag Sci (2010) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86
Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA (2005) 5.12
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis (2005) 3.50
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol (2011) 3.49
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Circadian variations of infarct size in acute myocardial infarction. Heart (2011) 2.60
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis (2005) 2.42
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol (2012) 2.38
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol (2004) 2.36
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA (2002) 2.29
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Distinguishing the temporal association between women's intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol (2006) 2.28
Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol (2002) 2.18
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer (2002) 2.10
Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol (2006) 2.04
The global cost of nonoptimal blood pressure. J Hypertens (2009) 2.00
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol (2006) 1.96
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol (2012) 1.79
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Risk factors of invasive cervical cancer in Mali. Int J Epidemiol (2002) 1.74
HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet (2002) 1.74
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
Legislating against use of cost-effectiveness information. N Engl J Med (2010) 1.68
News media coverage of human papillomavirus. Cancer (2004) 1.68
The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis (2002) 1.67
Environmental co-factors in HPV carcinogenesis. Virus Res (2002) 1.66
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
The 2001 Bethesda System terminology. Am Fam Physician (2003) 1.64
The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis (2005) 1.64
The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer (2004) 1.63
The Strong Protective Effect of Circumcision against Cancer of the Penis. Adv Urol (2011) 1.63
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer (2004) 1.62
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant (2012) 1.62
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer (2003) 1.61